Press release archive

Take a look at our press release archive.

  • 20 Oct 2016
    ThromboGenics Business Update – Q3 2016
  • 11 Oct 2016
    ThromboGenics’ Clinical Data to be Presented at 2016 AAO Meeting in Chicago
  • 5 Oct 2016
    ThromboGenics Presenting New Research Findings at the European Association for Vision and Eye Research (EVER) Congress in Nice
  • 7 Sep 2016
    ThromboGenics Presenting New Ophthalmic Research Data at 16th EURETINA Congress in Copenhagen
  • 25 Aug 2016
    ThromboGenics Business Update – H1 2016
  • 8 Aug 2016
    ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)
  • 3 Aug 2016
    ThromboGenics Presenting Ocriplasmin Research Findings at Upcoming ASRS 2016 Annual Scientific Meeting in San Francisco
  • 8 Jun 2016
    ThromboGenics Receives US FDA Approval for New ‘Already-Diluted’ Formulation of JETREA®
  • 7 Jun 2016
    ThromboGenics Highlights Diabetic Eye Drug Developments at ADA’s 76th Scientific Sessions Meeting in New Orleans
  • 13 May 2016
    ThromboGenics Business Update – Q1 2016
  • 2 May 2016
    Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma
  • 27 Apr 2016
    New Ocriplasmin Research Findings Presented at Upcoming ARVO 2016 Annual Meeting in Seattle
  • 24 Mar 2016
    ThromboGenics To Present at Key Investor Meetings
  • 18 Mar 2016
    ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease in London Today
  • 17 Mar 2016
    ThromboGenics signs global and exclusive in-licensing agreement with Galapagos to develop and commercialize integrin antagonists for the treatment of diabetic eye disease
  • 17 Mar 2016
    ThromboGenics Full Year 2015 Business Update
  • 15 Mar 2016
    Oncurious NV and BioInvent Partner with US Research Consortium to accelerate Phase I/IIa clinical development of TB-403
  • 1 Mar 2016
    ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March
  • 14 Jan 2016
    Transparency Statement Thomas and Landon Clay
  • 13 Jan 2016
    ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
  • 8 Jan 2016
    ThromboGenics presenting ophthalmic research findings at Congress of the Academia Ophthalmologica Belgica
  • 7 Jan 2016
    Oncurious NV Announces FDA Acceptance of Investigational New Drug (IND) Application for a Phase I/IIa Study with TB-403 for the Treatment of Pediatric Brain Tumors